Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Jan 27, 2013; 5(1): 38-42
Published online Jan 27, 2013. doi: 10.4254/wjh.v5.i1.38
Published online Jan 27, 2013. doi: 10.4254/wjh.v5.i1.38
Table 3 Biochemical changes before transjugular intrahepatic portosystemic shunt and during follow up
Reference interval | Before TIPS | 6 mo | 12 mo | 24 mo | 36 mo | |
n | 14 | 11 | 11 | 11 | 10 | |
Alanine aminotransaminase (U/L) | (10-70) (M)/(10-45) (F) | 73 (15-533) | 41 (23-66) | 34 (22-62) | 42 (19-58) | 35 (11-77) |
Bilirubin (μmol/L) | 5-25 | 35 (10-86) | 28 (10-50) | 27 (4-94) | 25 (12-152) | 21 (14-85) |
Alkaline phosphatase (U/L) | 35-105 | 180 (22-1105) | 182 (86-391) | 186 (94-461) | 154 (88-358) | 154 (89-349) |
Albumin (μmol/L) | 542-722 | 466 (331-711) | 595 (439-707) | 601 (554-714) | 605 (532-684) | 622 (497-727) |
Creatinine (μmol/L) | (60-105) (M)/(45-90) (F) | 76 (19-119) | 71 (51-106) | 69 (49-98) | 71 (47-98) | 59 (45-86) |
- Citation: Neumann AB, Andersen SD, Nielsen DT, Holland-Fischer P, Vilstrup H, Grønbæk H. Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. World J Hepatol 2013; 5(1): 38-42
- URL: https://www.wjgnet.com/1948-5182/full/v5/i1/38.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i1.38